Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Condition(s)
Leukemia

Age Group
10-17 years 18-26 years 27 years and older

Phase(s)
1

Biological treatment cell Biological
UCART19
Trial Summary & Details
Ages: 16 Years to 69 Years
Condition: B-cell Acute Lymphoblastic Leukemia

The purpose of this study is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen.

Status
Recruiting
Location(s)
Massachusetts General Hospital, Boston, MA
Hospital of the University of Pennsylvania, Philadelphia, PA
University of Texas MD Anderson Cancer Center, Houston, TX
Hôpital Saint-Antoine, PARIS Cedex 12, France
Hôpital Saint-Louis, Paris, France
King's College Hospital NHS Foundation Trust, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom

Sponsor/Collaborators:
Institut de Recherches Internationales Servier, ADIR - a Servier Group Company
Contact
Institut de Recherches Internationales Servier
+33 1 55 72 43 66

Find out more

© 2014-2024 Emily Whitehead Foundation - Activate the Cure® for Childhood Cancer | All Rights Reserved

Privacy Policy